PRESCRIBING INFORMATION

# 2 FLONASE<sup>®</sup>

- 3 (fluticasone propionate)
- 4 Nasal Spray, 50 mcg
- 5

1

## 6 For Intranasal Use Only.


### 7 **DESCRIPTION**

8 Fluticasone propionate, the active component of FLONASE Nasal Spray, is a synthetic

9 corticosteroid having the chemical name S-(fluoromethyl) $6\alpha$ ,9-difluoro-11 $\beta$ -17-dihydroxy-16 $\alpha$ -

10 methyl-3-oxoandrosta-1,4-diene-17β-carbothioate, 17-propionate and the following chemical

- 11 structure:
- 12



13 14

15 Fluticasone propionate is a white to off-white powder with a molecular weight of 500.6, and

- 16 the empirical formula is  $C_{25}H_{31}F_3O_5S$ . It is practically insoluble in water, freely soluble in
- 17 dimethyl sulfoxide and dimethylformamide, and slightly soluble in methanol and 95% ethanol.

18 FLONASE Nasal Spray, 50 mcg is an aqueous suspension of microfine fluticasone propionate

19 for topical administration to the nasal mucosa by means of a metering, atomizing spray pump.

20 FLONASE Nasal Spray also contains microcrystalline cellulose and carboxymethylcellulose

sodium, dextrose, 0.02% w/w benzalkonium chloride, polysorbate 80, and 0.25% w/w

22 phenylethyl alcohol, and has a pH between 5 and 7.

23 It is necessary to prime the pump before first use or after a period of non-use (1 week or

24 more). After initial priming (6 actuations), each actuation delivers 50 mcg of fluticasone

25 propionate in 100 mg of formulation through the nasal adapter. Each 16-g bottle of FLONASE

26 Nasal Spray provides 120 metered sprays. After 120 metered sprays, the amount of fluticasone

27 propionate delivered per actuation may not be consistent and the unit should be discarded.

## 28 CLINICAL PHARMACOLOGY

29 Mechanism of Action: Fluticasone propionate is a synthetic, trifluorinated corticosteroid with

30 anti-inflammatory activity. In vitro dose response studies on a cloned human glucocorticoid

- 31 receptor system involving binding and gene expression afforded 50% responses at 1.25 and
- 32 0.17 nM concentrations, respectively. Fluticasone propionate was 3-fold to 5-fold more potent
- than dexamethasone in these assays. Data from the McKenzie vasoconstrictor assay in man also
- 34 support its potent glucocorticoid activity.

## SHAKE GENTLY BEFORE USE.

35 In preclinical studies, fluticasone propionate revealed progesterone-like activity similar to the

36 natural hormone. However, the clinical significance of these findings in relation to the low

- 37 plasma levels (see Pharmacokinetics) is not known.
- 38 The precise mechanism through which fluticasone propionate affects allergic rhinitis
- 39 symptoms is not known. Corticosteroids have been shown to have a wide range of effects on
- 40 multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes)
- 41 and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in
- 42 inflammation. In 7 trials in adults, FLONASE Nasal Spray has decreased nasal mucosal
- 43 eosinophils in 66% (35% for placebo) of patients and basophils in 39% (28% for placebo) of
- 44 patients. The direct relationship of these findings to long-term symptom relief is not known.
- 45 FLONASE Nasal Spray, like other corticosteroids, is an agent that does not have an
- 46 immediate effect on allergic symptoms. A decrease in nasal symptoms has been noted in some
- 47 patients 12 hours after initial treatment with FLONASE Nasal Spray. Maximum benefit may not
- 48 be reached for several days. Similarly, when corticosteroids are discontinued, symptoms may not49 return for several days.
- 50 Pharmacokinetics: *Absorption:* The activity of FLONASE Nasal Spray is due to the parent
- 51 drug, fluticasone propionate. Indirect calculations indicate that fluticasone propionate delivered
- 52 by the intranasal route has an absolute bioavailability averaging less than 2%. After intranasal
- 53 treatment of patients with allergic rhinitis for 3 weeks, fluticasone propionate plasma
- 54 concentrations were above the level of detection (50 pg/mL) only when recommended doses
- 55 were exceeded and then only in occasional samples at low plasma levels. Due to the low
- 56 bioavailability by the intranasal route, the majority of the pharmacokinetic data was obtained via
- 57 other routes of administration. Studies using oral dosing of radiolabeled drug have demonstrated
- 58 that fluticasone propionate is highly extracted from plasma and absorption is low. Oral
- bioavailability is negligible, and the majority of the circulating radioactivity is due to an inactivemetabolite.
- 61 *Distribution:* Following intravenous administration, the initial disposition phase for
- 62 fluticasone propionate was rapid and consistent with its high lipid solubility and tissue binding.
- 63 The volume of distribution averaged 4.2 L/kg.
- 64 The percentage of fluticasone propionate bound to human plasma proteins averaged 91% with 65 no obvious concentration relationship. Fluticasone propionate is weakly and reversibly bound to 66 erythrocytes and freely equilibrates between erythrocytes and plasma. Fluticasone propionate is 67 not significantly bound to human transcortin
- 67 not significantly bound to human transcortin.
- 68 *Metabolism:* The total blood clearance of fluticasone propionate is high (average,
- 69 1,093 mL/min), with renal clearance accounting for less than 0.02% of the total. The only
- 70 circulating metabolite detected in man is the 17β-carboxylic acid derivative of fluticasone
- 71 propionate, which is formed through the cytochrome P450 3A4 pathway. This inactive
- 72 metabolite had less affinity (approximately 1/2,000) than the parent drug for the glucocorticoid
- 73 receptor of human lung cytosol in vitro and negligible pharmacological activity in animal

studies. Other metabolites detected in vitro using cultured human hepatoma cells have not beendetected in man.

- 76 *Elimination:* Following intravenous dosing, fluticasone propionate showed polyexponential
- 77 kinetics and had a terminal elimination half-life of approximately 7.8 hours. Less than 5% of a
- radiolabeled oral dose was excreted in the urine as metabolites, with the remainder excreted in
- 79 the feces as parent drug and metabolites.
- 80 Special Populations: Fluticasone propionate nasal spray was not studied in any special
- 81 populations, and no gender-specific pharmacokinetic data have been obtained.
- 82 **Drug Interactions:** Fluticasone propionate is a substrate of cytochrome P450 3A4.
- 83 Coadministration of fluticasone propionate and the highly potent cytochrome P450 3A4 inhibitor
- ritonavir is not recommended based upon a multiple-dose, crossover drug interaction study in 18
- 85 healthy subjects. Fluticasone propionate aqueous nasal spray (200 mcg once daily) was
- 86 coadministered for 7 days with ritonavir (100 mg twice daily). Plasma fluticasone propionate
- 87 concentrations following fluticasone propionate aqueous nasal spray alone were undetectable
- (<10 pg/mL) in most subjects, and when concentrations were detectable peak levels ( $C_{max}$
- 89 averaged 11.9 pg/mL [range, 10.8 to 14.1 pg/mL] and AUC<sub> $(0-\tau)$ </sub> averaged 8.43 pg•hr/mL [range,
- 90 4.2 to 18.8 pg•hr/mL]). Fluticasone propionate  $C_{max}$  and  $AUC_{(0-\tau)}$  increased to 318 pg/mL (range,
- 91 110 to 648 pg/mL) and 3,102.6 pg•hr/mL (range, 1,207.1 to 5,662.0 pg•hr/mL), respectively,
- 92 after coadministration of ritonavir with fluticasone propionate aqueous nasal spray. This
- 93 significant increase in plasma fluticasone propionate exposure resulted in a significant decrease
- 94 (86%) in plasma cortisol area under the plasma concentration versus time curve (AUC).
- 95 Caution should be exercised when other potent cytochrome P450 3A4 inhibitors are 96 coadministered with fluticasone propionate In a drug interaction study, coadministration of orally 97 inhaled fluticasone propionate (1,000 mcg) and ketoconazole (200 mg once daily) resulted in
- 98 increased fluticasone propionate exposure and reduced plasma cortisol AUC, but had no effect99 on urinary excretion of cortisol.
- 100 In another multiple-dose drug interaction study, coadministration of orally inhaled fluticasone
- 101 propionate (500 mcg twice daily) and erythromycin (333 mg 3 times daily) did not affect
- 102 fluticasone propionate pharmacokinetics.
- 103 **Pharmacodynamics:** In a trial to evaluate the potential systemic and topical effects of
- 104 FLONASE Nasal Spray on allergic rhinitis symptoms, the benefits of comparable drug blood
- 105 levels produced by FLONASE Nasal Spray and oral fluticasone propionate were compared. The
- 106 doses used were 200 mcg of FLONASE Nasal Spray, the nasal spray vehicle (plus oral placebo),
- 107 and 5 and 10 mg of oral fluticasone propionate (plus nasal spray vehicle) per day for 14 days.
- 108 Plasma levels were undetectable in the majority of patients after intranasal dosing, but present at
- 109 low levels in the majority after oral dosing. FLONASE Nasal Spray was significantly more
- 110 effective in reducing symptoms of allergic rhinitis than either the oral fluticasone propionate or
- 111 the nasal vehicle. This trial demonstrated that the therapeutic effect of FLONASE Nasal Spray
- 112 can be attributed to the topical effects of fluticasone propionate.

- 113 In another trial, the potential systemic effects of FLONASE Nasal Spray on the
- 114 hypothalamic-pituitary-adrenal (HPA) axis were also studied in allergic patients. FLONASE
- 115 Nasal Spray given as 200 mcg once daily or 400 mcg twice daily was compared with placebo or
- oral prednisone 7.5 or 15 mg given in the morning. FLONASE Nasal Spray at either dose for 4
- 117 weeks did not affect the adrenal response to 6-hour cosyntropin stimulation, while both doses of
- 118 oral prednisone significantly reduced the response to cosyntropin.
- 119 **Clinical Trials:** A total of 13 randomized, double-blind, parallel-group, multicenter, vehicle
- 120 placebo-controlled clinical trials were conducted in the United States in adults and pediatric
- 121 patients (4 years of age and older) to investigate regular use of FLONASE Nasal Spray in
- patients with seasonal or perennial allergic rhinitis. The trials included 2,633 adults (1,439 men
- and 1,194 women) with a mean age of 37 (range, 18 to 79 years). A total of 440 adolescents (405
- boys and 35 girls), mean age of 14 (range, 12 to 17 years), and 500 children (325 boys and 175
- girls), mean age of 9 (range, 4 to 11 years) were also studied. The overall racial distribution was
- 126 89% white, 4% black, and 7% other. These trials evaluated the total nasal symptom scores
- 127 (TNSS) that included rhinorrhea, nasal obstruction, sneezing, and nasal itching in known allergic
- 128 patients who were treated for 2 to 24 weeks. Subjects treated with FLONASE Nasal Spray
- exhibited significantly greater decreases in TNSS than vehicle placebo-treated patients. Nasal
- 130 mucosal basophils and eosinophils were also reduced at the end of treatment in adult studies;
- 131 however, the clinical significance of this decrease is not known.
- There were no significant differences between fluticasone propionate regimens whether administered as a single daily dose of 200 mcg (two 50-mcg sprays in each nostril) or as 100 mcg (one 50-mcg spray in each nostril) twice daily in 6 clinical trials. A clear dose response could not be identified in clinical trials. In 1 trial, 200 mcg/day was slightly more effective than 50 mcg/day during the first few days of treatment; thereafter, no difference was seen.
- Two randomized, double-blind, parallel-group, multicenter, vehicle placebo-controlled 28-day
  trials were conducted in the United States in 732 patients (243 given FLONASE) 12 years of age
  and older to investigate "as-needed" use of FLONASE Nasal Spray (200 mcg) in patients with
- 140 seasonal allergic rhinitis. Patients were instructed to take the study medication only on days
- 141 when they thought they needed the medication for symptom control, not to exceed 2 sprays per
- nostril on any day, and not more than once daily. "As-needed" use was prospectively defined as
- average use of study medication no more than 75% of study days. Average use of study
- 144 medications was 57% to 70% of days for all treatment arms. The studies demonstrated
- significantly greater reduction in TNSS (sum of nasal congestion, rhinorrhea, sneezing, and nasal
- 146 itching) with FLONASE Nasal Spray 200 mcg compared to placebo. The relative difference in
- 147 efficacy with as-needed use as compared to regularly administered doses was not studied.
- 148 Three randomized, double-blind, parallel-group, vehicle placebo-controlled trials were
- 149 conducted in 1,191 patients to investigate regular use of FLONASE Nasal Spray in patients with
- 150 perennial nonallergic rhinitis. These trials evaluated the patient-rated TNSS (nasal obstruction,
- postnasal drip, rhinorrhea) in patients treated for 28 days of double-blind therapy and in 1 of the
- 152 3 trials for 6 months of open-label treatment. Two of these trials demonstrated that patients

- treated with FLONASE Nasal Spray at a dose of 100 mcg twice daily exhibited statistically
- 154 significant decreases in TNSS compared with patients treated with vehicle.
- 155 Individualization of Dosage: Patients should use FLONASE Nasal Spray at regular intervals

156 for optimal effect.

- 157 Adult patients may be started on a 200-mcg once-daily regimen (two 50-mcg sprays in each
- nostril once daily). An alternative 200-mcg/day dosage regimen can be given as 100 mcg twice
- 159 daily (one 50-mcg spray in each nostril twice daily).
- 160 Individual patients will experience a variable time to onset and different degree of symptom
- relief. In 4 randomized, double-blind, vehicle placebo-controlled, parallel-group allergic rhinitis
- 162 studies and 2 studies of patients in an outdoor "park" setting (park studies), a decrease in nasal
- 163 symptoms in treated subjects compared to placebo was shown to occur as soon as 12 hours after 164 treatment with a 200-mcg dose of FLONASE Nasal Spray. Maximum effect may take several
- 164 treatment with a 200-mcg dose of FLONASE Nasal Spray. Maximum effect may take several 165 days. Regular-use patients who have responded may be able to be maintained (after 4 to 7 days)
- 166 on 100 mcg/day (1 spray in each nostril once daily).
- 167 Some patients (12 years of age and older) with seasonal allergic rhinitis may find as-needed
- 168 use of FLONASE Nasal Spray (not to exceed 200 mcg daily) effective for symptom control (see
- 169 Clinical Trials). Greater symptom control may be achieved with scheduled regular use. Efficacy
- 170 of as-needed use of FLONASE Nasal Spray has not been studied in pediatric patients under 12
- 171 years of age with seasonal allergic rhinitis, or patients with perennial allergic or nonallergic
- 172 rhinitis.
- Pediatric patients (4 years of age and older) should be started with 100 mcg (1 spray in each
- nostril once daily). Treatment with 200 mcg (2 sprays in each nostril once daily or 1 spray in
- each nostril twice daily) should be reserved for pediatric patients not adequately responding to
- 176 100 mcg daily. Once adequate control is achieved, the dosage should be decreased to 100 mcg (1
- 177 spray in each nostril) daily.
- 178 Maximum total daily doses should not exceed 2 sprays in each nostril (total dose,
- 179 200 mcg/day). There is no evidence that exceeding the recommended dose is more effective.

## 180 INDICATIONS AND USAGE

- 181 FLONASE Nasal Spray is indicated for the management of the nasal symptoms of seasonal
- and perennial allergic and nonallergic rhinitis in adults and pediatric patients 4 years of age andolder.
- 184 Safety and effectiveness of FLONASE Nasal Spray in children below 4 years of age have not185 been adequately established.

## 186 CONTRAINDICATIONS

FLONASE Nasal Spray is contraindicated in patients with a hypersensitivity to any of itsingredients.

### 189 (WARNINGS)

190 The replacement of a systemic corticosteroid with a topical corticosteroid can be accompanied 191 by signs of adrenal insufficiency, and in addition some patients may experience symptoms of 192 withdrawal, e.g., joint and/or muscular pain, lassitude, and depression. Patients previously 193 treated for prolonged periods with systemic corticosteroids and transferred to topical 194 corticosteroids should be carefully monitored for acute adrenal insufficiency in response to 195 stress. In those patients who have asthma or other clinical conditions requiring long-term 196 systemic corticosteroid treatment, too rapid a decrease in systemic corticosteroids may cause a 197 severe exacerbation of their symptoms.

198 The concomitant use of intranasal corticosteroids with other inhaled corticosteroids could 199 increase the risk of signs or symptoms of hypercorticism and/or suppression of the HPA axis.

A drug interaction study in healthy subjects has shown that ritonavir (a highly potent

201 cytochrome P450 3A4 inhibitor) can significantly increase plasma fluticasone propionate

202 exposure, resulting in significantly reduced serum cortisol concentrations (see CLINICAL

203 PHARMACOLOGY: Drug Interactions and PRECAUTIONS: Drug Interactions). During

204 postmarketing use, there have been reports of clinically significant drug interactions in patients

receiving fluticasone propionate and ritonavir, resulting in systemic corticosteroid effects
 including Cushing syndrome and adrenal suppression. Therefore, coadministration of fluticasone

- propionate and ritonavir is not recommended unless the potential benefit to the patient
- 208 outweighs the risk of systemic corticosteroid side effects.

209 Persons who are using drugs that suppress the immune system are more susceptible to 210 infections than healthy individuals. Chickenpox and measles, for example, can have a more 211 serious or even fatal course in susceptible children or adults using corticosteroids. In children or 212 adults who have not had these diseases or been properly immunized, particular care should be 213 taken to avoid exposure. How the dose, route, and duration of corticosteroid administration affect 214 the risk of developing a disseminated infection is not known. The contribution of the underlying 215 disease and/or prior corticosteroid treatment to the risk is also not known. If exposed to 216 chickenpox, prophylaxis with varicella zoster immune globulin (VZIG) may be indicated. If 217 exposed to measles, prophylaxis with pooled intramuscular immunoglobulin (IG) may be

218 indicated. (See the respective package inserts for complete VZIG and IG prescribing

219 information.) If chickenpox develops, treatment with antiviral agents may be considered.

Avoid spraying in eyes.

## 221 **PRECAUTIONS**

222 General: Intranasal corticosteroids may cause a reduction in growth velocity when administered

to pediatric patients (see PRECAUTIONS: Pediatric Use).

224 Rarely, immediate hypersensitivity reactions or contact dermatitis may occur after the

administration of FLONASE Nasal Spray. Rare instances of wheezing, nasal septum perforation,

226 cataracts, glaucoma, and increased intraocular pressure have been reported following the

227 intranasal application of corticosteroids, including fluticasone propionate.

Use of excessive doses of corticosteroids may lead to signs or symptoms of hypercorticismand/or suppression of HPA function.

Although systemic effects have been minimal with recommended doses of FLONASE Nasal
 Spray, potential risk increases with larger doses. Therefore, larger than recommended doses of
 FLONASE Nasal Spray should be avoided.

When used at higher than recommended doses or in rare individuals at recommended doses, systemic corticosteroid effects such as hypercorticism and adrenal suppression may appear. If

systemic controls checks such as hypercontents in and datenal suppression may appear. In such changes occur, the dosage of FLONASE Nasal Spray should be discontinued slowly

236 consistent with accepted procedures for discontinuing oral corticosteroid therapy.

237 In clinical studies with fluticasone propionate administered intranasally, the development of

localized infections of the nose and pharynx with *Candida albicans* has occurred only rarely.

239 When such an infection develops, it may require treatment with appropriate local therapy and

240 discontinuation of treatment with FLONASE Nasal Spray. Patients using FLONASE Nasal

Spray over several months or longer should be examined periodically for evidence of *Candida* 

242 infection or other signs of adverse effects on the nasal mucosa.

243 Intranasal corticosteroids should be used with caution, if at all, in patients with active or

quiescent tuberculous infections of the respiratory tract; untreated local or systemic fungal orbacterial infections; systemic viral or parasitic infections; or ocular herpes simplex.

Because of the inhibitory effect of corticosteroids on wound healing, patients who have
experienced recent nasal septal ulcers, nasal surgery, or nasal trauma should not use a nasal
corticosteroid until healing has occurred.

Information for Patients: Patients being treated with FLONASE Nasal Spray should receive the following information and instructions. This information is intended to aid them in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.

Patients should be warned to avoid exposure to chickenpox or measles and, if exposed, to consult their physician without delay.

255 Patients should use FLONASE Nasal Spray at regular intervals for optimal effect. Some

256 patients (12 years of age and older) with seasonal allergic rhinitis may find as-needed use of

257 200 mcg once daily effective for symptom control (see Clinical Trials).

A decrease in nasal symptoms may occur as soon as 12 hours after starting therapy with FLONASE Nasal Spray. Results in several clinical trials indicate statistically significant

260 improvement within the first day or two of treatment; however, the full benefit of FLONASE

261 Nasal Spray may not be achieved until treatment has been administered for several days. The

262 patient should not increase the prescribed dosage but should contact the physician if symptoms

263 do not improve or if the condition worsens.

264 For the proper use of FLONASE Nasal Spray and to attain maximum improvement, the

265 patient should read and follow carefully the patient's instructions accompanying the product.

266 (**Drug Interactions:** Fluticasone propionate is a substrate of cytochrome P450 3A4. A drug

267 interaction study with fluticasone propionate aqueous nasal spray in healthy subjects has shown

- that ritonavir (a highly potent cytochrome P450 3A4 inhibitor) can significantly increase plasma
- 269 fluticasone propionate exposure, resulting in significantly reduced serum cortisol concentrations
- 270 (see CLINICAL PHARMACOLOGY: Drug Interactions). During postmarketing use, there have
- 271 been reports of clinically significant drug interactions in patients receiving fluticasone propionate
- and ritonavir, resulting in systemic corticosteroid effects including Cushing syndrome and
- adrenal suppression. Therefore, coadministration of fluticasone propionate and ritonavir is not
- recommended unless the potential benefit to the patient outweighs the risk of systemic
- 275 corticosteroid side effects.
- In a placebo-controlled, crossover study in 8 healthy volunteers, coadministration of a single
- dose of orally inhaled fluticasone propionate (1,000 mcg; 5 times the maximum daily intranasal
- dose) with multiple doses of ketoconazole (200 mg) to steady state resulted in increased plasma
- 279 fluticasone propionate exposure, a reduction in plasma cortisol AUC, and no effect on urinary
- excretion of cortisol. Caution should be exercised when FLONASE Nasal Spray is
- coadministered with ketoconazole and other known potent cytochrome P450 3A4 inhibitors.

282 Carcinogenesis, Mutagenesis, Impairment of Fertility: Fluticasone propionate

- 283 demonstrated no tumorigenic potential in mice at oral doses up to 1,000 mcg/kg (approximately
- 284 20 times the maximum recommended daily intranasal dose in adults and approximately 10 times
- the maximum recommended daily intranasal dose in children on a  $mcg/m^2$  basis) for 78 weeks or
- in rats at inhalation doses up to 57 mcg/kg (approximately 2 times the maximum recommended
- daily intranasal dose in adults and approximately equivalent to the maximum recommended daily intranasal dose in children on a  $mcg/m^2$  basis) for 104 weeks.
- Fluticasone propionate did not induce gene mutation in prokaryotic or eukaryotic cells in vitro. No significant clastogenic effect was seen in cultured human peripheral lymphocytes in vitro or in the mouse micronucleus test.
- 292 No evidence of impairment of fertility was observed in reproductive studies conducted in
- 293 male and female rats at subcutaneous doses up to 50 mcg/kg (approximately 2 times the
- 294 maximum recommended daily intranasal dose in adults on a mcg/m<sup>2</sup> basis). Prostate weight was
- significantly reduced at a subcutaneous dose of 50 mcg/kg.
- Pregnancy: Teratogenic Effects: Pregnancy Category C. Subcutaneous studies in the mouse and rat at 45 and 100 mcg/kg, respectively (approximately equivalent to and 4 times the maximum recommended daily intranasal dose in adults on a mcg/m<sup>2</sup> basis, respectively) revealed
- 299 fetal toxicity characteristic of potent corticosteroid compounds, including embryonic growth
- 300 retardation, omphalocele, cleft palate, and retarded cranial ossification.
- 301 In the rabbit, fetal weight reduction and cleft palate were observed at a subcutaneous dose of

4 mcg/kg (less than the maximum recommended daily intranasal dose in adults on a mcg/m<sup>2</sup>

- 303 basis). However, no teratogenic effects were reported at oral doses up to 300 mcg/kg
- 304 (approximately 25 times the maximum recommended daily intranasal dose in adults on a  $mcg/m^2$
- basis) of fluticasone propionate to the rabbit. No fluticasone propionate was detected in the
- 306 plasma in this study, consistent with the established low bioavailability following oral
- 307 administration (see CLINICAL PHARMACOLOGY).

- 308 Fluticasone propionate crossed the placenta following oral administration of 100 mcg/kg to
- rats or 300 mcg/kg to rabbits (approximately 4 and 25 times, respectively, the maximum
- 310 recommended daily intranasal dose in adults on a  $mcg/m^2$  basis).
- There are no adequate and well-controlled studies in pregnant women. Fluticasone propionate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
- Experience with oral corticosteroids since their introduction in pharmacologic, as opposed to
- 315 physiologic, doses suggests that rodents are more prone to teratogenic effects from
- 316 corticosteroids than humans. In addition, because there is a natural increase in corticosteroid
- 317 production during pregnancy, most women will require a lower exogenous corticosteroid dose
- 318 and many will not need corticosteroid treatment during pregnancy.
- 319 **Nursing Mothers:** It is not known whether fluticasone propionate is excreted in human breast
- 320 milk. However, other corticosteroids have been detected in human milk. Subcutaneous
- 321 administration to lactating rats of 10 mcg/kg of tritiated fluticasone propionate (less than the
- 322 maximum recommended daily intranasal dose in adults on a mcg/m<sup>2</sup> basis) resulted in
- 323 measurable radioactivity in the milk. Since there are no data from controlled trials on the use of
- 324 intranasal fluticasone propionate by nursing mothers, caution should be exercised when
- 325 FLONASE Nasal Spray is administered to a nursing woman.
- **Pediatric Use:** Six hundred fifty (650) patients aged 4 to 11 years and 440 patients aged 12 to
- 327 17 years were studied in US clinical trials with fluticasone propionate nasal spray. The safety and
- 328 effectiveness of FLONASE Nasal Spray in children below 4 years of age have not been
- 329 established.
- Controlled clinical studies have shown that intranasal corticosteroids may cause a reduction in
   growth velocity in pediatric patients. This effect has been observed in the absence of laboratory
- 332 evidence of HPA axis suppression, suggesting that growth velocity is a more sensitive indicator
- 333 of systemic corticosteroid exposure in pediatric patients than some commonly used tests of HPA
- axis function. The long-term effects of this reduction in growth velocity associated with
- intranasal corticosteroids, including the impact on final adult height, are unknown. The potential
- 336 for "catch-up" growth following discontinuation of treatment with intranasal corticosteroids has
- 337 not been adequately studied. The growth of pediatric patients receiving intranasal corticosteroids,
- including FLONASE Nasal Spray, should be monitored routinely (e.g., via stadiometry). The
- 339 potential growth effects of prolonged treatment should be weighed against the clinical benefits
- 340 obtained and the risks/benefits of treatment alternatives. To minimize the systemic effects of
- intranasal corticosteroids, including FLONASE Nasal Spray, each patient should be titrated to
- 342 the lowest dose that effectively controls his/her symptoms.
- A 1-year placebo-controlled clinical growth study was conducted in 150 pediatric patients
- 344 (ages 3 to 9 years) to assess the effect of FLONASE Nasal Spray (single daily dose of 200 mcg,
- 345 the maximum approved dose) on growth velocity. From the primary population of 56 patients
- receiving FLONASE Nasal Spray and 52 receiving placebo, the point estimate for growth
- 347 velocity with FLONASE Nasal Spray was 0.14 cm/year lower than that noted with placebo (95%

348 confidence interval ranging from 0.54 cm/year lower than placebo to 0.27 cm/year higher than

349 placebo). Thus, no statistically significant effect on growth was noted compared to placebo. No

350 evidence of clinically relevant changes in HPA axis function or bone mineral density was

351 observed as assessed by 12-hour urinary cortisol excretion and dual-energy x-ray absorptiometry,

- 352 respectively.
- 353

354 The potential for FLONASE Nasal Spray to cause growth suppression in susceptible patients 355 or when given at higher doses cannot be ruled out.

356

357 **Geriatric Use:** A limited number of patients 65 years of age and older (n = 129) or 75 years of 358 age and older (n = 11) have been treated with FLONASE Nasal Spray in US and non-US clinical

359 trials. While the number of patients is too small to permit separate analysis of efficacy and

360 safety, the adverse reactions reported in this population were similar to those reported by

361 younger patients.

#### 362 **ADVERSE REACTIONS**

363 In controlled US studies, more than 3,300 patients with seasonal allergic, perennial allergic, or 364 perennial nonallergic rhinitis received treatment with intranasal fluticasone propionate. In 365 general, adverse reactions in clinical studies have been primarily associated with irritation of the nasal mucous membranes, and the adverse reactions were reported with approximately the same 366 367 frequency by patients treated with the vehicle itself. The complaints did not usually interfere 368 with treatment. Less than 2% of patients in clinical trials discontinued because of adverse events;

369 this rate was similar for vehicle placebo and active comparators.

370 Systemic corticosteroid side effects were not reported during controlled clinical studies up to

371 6 months' duration with FLONASE Nasal Spray. If recommended doses are exceeded, however,

372 or if individuals are particularly sensitive or taking FLONASE Nasal Spray in conjunction with

373 administration of other corticosteroids, symptoms of hypercorticism, e.g., Cushing syndrome,

374 could occur.

375 The following incidence of common adverse reactions (>3%, where incidence in fluticasone 376

propionate-treated subjects exceeded placebo) is based upon 7 controlled clinical trials in which

377 536 patients (57 girls and 108 boys aged 4 to11 years, 137 female and 234 male adolescents and

adults) were treated with FLONASE Nasal Spray 200 mcg once daily over 2 to 4 weeks and 2 378

379 controlled clinical trials in which 246 patients (119 female and 127 male adolescents and adults)

380 were treated with FLONASE Nasal Spray 200 mcg once daily over 6 months. Also included in 381 the table are adverse events from 2 studies in which 167 children (45 girls and 122 boys aged 4

382 to11 years) were treated with FLONASE Nasal Spray 100 mcg once daily for 2 to 4 weeks.

383

## 384 Overall Adverse Experiences With >3% Incidence on Fluticasone Propionate in Controlled

385 Clinical Trials With FLONASE Nasal Spray in Patients ≥4 Years With Seasonal or

		FLONASE	FLONASE"
	Vehicle Placebo	100 mcg Once Daily	200 mcg Once Daily
	(n = 758)	(n = 167)	(n = 782)
Adverse Experience	%	%	%
Headache	14.6	6.6	16.1
Pharyngitis	7.2	6.0	7.8
Epistaxis	5.4	6.0	6.9
Nasal burning/nasal irritation	2.6	2.4	3.2
Nausea/vomiting	2.0	4.8	2.6
Asthma symptoms	2.9	7.2	3.3
Cough	2.8	3.6	3.8

386 **Perennial Allergic Rhinitis** 

387

388 Other adverse events that occurred in  $\leq 3\%$  but  $\geq 1\%$  of patients and that were more common

389 with fluticasone propionate (with uncertain relationship to treatment) included: blood in nasal

390 mucus, runny nose, abdominal pain, diarrhea, fever, flu-like symptoms, aches and pains,

391 dizziness, bronchitis.

392 **Observed During Clinical Practice:** In addition to adverse events reported from clinical

trials, the following events have been identified during postapproval use of intranasal fluticasone

394 propionate in clinical practice. Because they are reported voluntarily from a population of

395 unknown size, estimates of frequency cannot be made. These events have been chosen for

inclusion due to either their seriousness, frequency of reporting, or causal connection to

397 fluticasone propionate or a combination of these factors.

398 General: Hypersensitivity reactions, including angioedema, skin rash, edema of the face and
 399 tongue, pruritus, urticaria, bronchospasm, wheezing, dyspnea, and anaphylaxis/anaphylactoid
 400 reactions, which in rare instances were severe.

401 *Ear, Nose, and Throat:* Alteration or loss of sense of taste and/or smell and, rarely, nasal
 402 septal perforation, nasal ulcer, sore throat, throat irritation and dryness, cough, hoarseness, and
 403 voice changes.

404 *Eye:* Dryness and irritation, conjunctivitis, blurred vision, glaucoma, increased intraocular
 405 pressure, and cataracts.

406 Cases of growth suppression have been reported for intranasal corticosteroids, including
407 FLONASE (see PRECAUTIONS: Pediatric Use).

## 408 **OVERDOSAGE**

409 Chronic overdosage may result in signs/symptoms of hypercorticism (see PRECAUTIONS).

410 Intranasal administration of 2 mg (10 times the recommended dose) of fluticasone propionate

411 twice daily for 7 days to healthy human volunteers was well tolerated. Single oral doses up to

- 412 16 mg have been studied in human volunteers with no acute toxic effects reported. Repeat oral
- doses up to 80 mg daily for 10 days in volunteers and repeat oral doses up to 10 mg daily for
- 414 14 days in patients were well tolerated. Adverse reactions were of mild or moderate severity, and
- 415 incidences were similar in active and placebo treatment groups. Acute overdosage with this
- 416 dosage form is unlikely since 1 bottle of FLONASE Nasal Spray contains approximately 8 mg of
- 417 fluticasone propionate.
- The oral and subcutaneous median lethal doses in mice and rats were >1,000 mg/kg (>20,000
- and >41,000 times, respectively, the maximum recommended daily intranasal dose in adults and
- 420 >10,000 and >20,000 times, respectively, the maximum recommended daily intranasal dose in
- 421 children on a  $mg/m^2$  basis).

## 422 DOSAGE AND ADMINISTRATION

- 423 Patients should use FLONASE Nasal Spray at regular intervals for optimal effect.
- 424 Adults: The recommended starting dosage in adults is 2 sprays (50 mcg of fluticasone
- 425 propionate each) in each nostril once daily (total daily dose, 200 mcg). The same dosage divided
- 426 into 100 mcg given twice daily (e.g., 8 a.m. and 8 p.m.) is also effective. After the first few days,
- 427 patients may be able to reduce their dosage to 100 mcg (1 spray in each nostril) once daily for
- 428 maintenance therapy. Some patients (12 years of age and older) with seasonal allergic rhinitis
- 429 may find as-needed use of 200 mcg once daily effective for symptom control (see Clinical
- 430 Trials). Greater symptom control may be achieved with scheduled regular use.
- 431 Adolescents and Children (4 Years of Age and Older): Patients should be started with
- 432 100 mcg (1 spray in each nostril once daily). Patients not adequately responding to 100 mcg may
- 433 use 200 mcg (2 sprays in each nostril). Once adequate control is achieved, the dosage should be
- 434 decreased to 100 mcg (1 spray in each nostril) daily.
- The maximum total daily dosage should not exceed 2 sprays in each nostril (200 mcg/day).
- 436 (See Individualization of Dosage and Clinical Trials sections.)
- 437 FLONASE Nasal Spray is not recommended for children under 4 years of age.
- 438 **Directions for Use:** Illustrated patient's instructions for proper use accompany each package
- 439 of FLONASE Nasal Spray.

## 440 HOW SUPPLIED

- 441 FLONASE Nasal Spray 50 mcg is supplied in an amber glass bottle fitted with a white
- 442 metering atomizing pump, white nasal adapter, and green dust cover in a box of 1 (NDC 0173-
- 443 0453-01) with patient's instructions for use. Each bottle contains a net fill weight of 16 g and
- 444 will provide 120 actuations. Each actuation delivers 50 mcg of fluticasone propionate in 100 mg
- of formulation through the nasal adapter. The correct amount of medication in each spray cannot
- be assured after 120 sprays even though the bottle is not completely empty. The bottle should be
- 447 discarded when the labeled number of actuations has been used.
- 448 Store between 4° and 30°C (39° and 86°F).
- 449
- 450



- 451 452 GlaxoSmithKline
- 453 Research Triangle Park, NC 27709
- 454
- 455 ©Year, GlaxoSmithKline. All rights reserved.
- 456
- 457 Month Year

RL-





Please read this leaflet carefully before you start to take your medicine. It provides a summary of information on your medicine.

For further information ask your doctor or pharmacist.

#### WHAT YOU SHOULD KNOW ABOUT RHINITIS

Rhinitis is a word that means inflammation of the lining of the nose. If you suffer from rhinitis, your nose becomes stuffy and runny. Rhinitis can also make your nose itchy, and you may sneeze a lot. Rhinitis can be caused by allergies to pollen, animals, molds, or other materials—or it may have a nonallergic cause.

#### WHAT YOU SHOULD KNOW ABOUT FLONASE NASAL SPRAY

Your doctor has prescribed FLONASE Nasal Spray, a medicine that can help treat your rhinitis. FLONASE Nasal Spray contains fluticasone propionate, which is a synthetic corticosteroid. Corticosteroids are natural substances found in the body that help fight inflammation. When you spray FLONASE into your nose, it helps to reduce the symptoms of allergic reactions and the stuffiness, runniness, itching, and sneezing that can bother you.

#### THINGS TO REMEMBER ABOUT FLONASE NASAL SPRAY

- 1. Shake gently before using.
- 2. Use your nasal spray as directed by your doctor. The directions are on the pharmacy label.
- 3. Keep your nasal spray out of the reach of children.

#### **BEFORE USING YOUR NASAL SPRAY**

- If you are pregnant (or intending to become pregnant),
- If you are breastfeeding a baby,
- If you are allergic to FLONASE Nasal Spray or any other nasal corticosteroid,
- If you are taking a medicine containing ritonavir (commonly used to treat HIV infection or AIDS),

**TELL YOUR DOCTOR BEFORE STARTING TO TAKE THIS MEDI-CINE.** In some circumstances, this medicine may not be suitable and your doctor may wish to give you a different medicine. Make sure that your doctor knows what other medicines you are taking.

### **USING YOUR NASAL SPRAY**

- Follow the instructions shown in the rest of this leaflet. If you have any problems, tell your doctor or pharmacist.
- It is important that you use it as directed by your doctor. The pharmacist's label will usually tell you what dose to take and how often. If it doesn't, or you are not sure, ask your doctor or pharmacist.

#### DOSAGE

\* For ADULTS, the usual starting dosage is 2 sprays in each nostril

*once daily.* Sometimes your doctor may recommend using 1 spray in each nostril twice a day (morning and evening). You should not use more than a total of 2 sprays in each nostril daily. After you have begun to feel better, 1 spray in each nostril daily may be adequate for you.

For **ADOLESCENTS and CHILDREN** (4 years of age and older), the usual starting dosage is **1** spray in each nostril once daily. Sometimes your doctor may recommend using 2 sprays in each nostril daily. Then, after you have begun to feel better, 1 spray in each nostril daily may be adequate for you.

- DO NOT use more of your medicine or take it more often than your doctor advises.
- FLONASE may begin to work within 12 hours of the first dose, but it takes several days of regular use to reach its greatest effect. It is important that you use FLONASE Nasal Spray as prescribed by your doctor. Best results will be obtained by using the spray on a regular basis. If symptoms disappear, contact your doctor for further instructions.
- If you also have itchy, watery eyes, you should tell your doctor. You may be given an additional medicine to treat your eyes. Be careful not to confuse them, particularly if the second medicine is an eye drop.
- If you miss a dose, just take your regularly scheduled next dose when it is due. DO NOT DOUBLE the dose.

#### HOW TO USE YOUR NASAL SPRAY



Read the complete instructions carefully and use only as directed.


#### **BEFORE USING**

Shake the bottle gently and
then remove the dust cover (Figure 1).

FIGURE <sup>-</sup>



FIGURE 2



The pump is now ready for use. If the pump is not used for 7 days, prime until a fine spray appears.



FIGURE 3

#### USING THE SPRAY

**3.** Blow your nose to clear your nostrils.

**4.** Close one nostril. Tilt your head forward slightly and, keeping the bottle upright, carefully insert the nasal applicator into the other nostril (Figure 3).



FIGURE 4

FIGURE 5

**5.** Start to breathe in through your nose, and WHILE

BREATHING IN press firmly and quickly down once on the applicator to release the spray. To get a full actuation, use your forefinger and middle finger to spray while supporting the base of the bottle with your thumb. Avoid spraying in eyes. Breathe gently inwards through the nostril (Figure 4).

**6** Breathe out through your mouth.

7. If a second spray is required in that nostril, repeat steps 4 through 6.

**8** Repeat steps 4 through 7 in the other nostril.

**9.** Wipe the nasal applicator with a clean tissue and replace the dust cover (Figure 5).

**10.** Do not use this bottle for more than the labeled number of sprays even though the bottle is not completely empty. Before you throw the bottle away, you should consult your doctor to see if a refill is needed. Do not take extra doses or stop taking FLONASE Nasal Spray without consulting your doctor.

#### CLEANING

Your nasal spray should be cleaned at least once a week. To do this:

- 1. Remove the dust cover and then gently pull upwards to free the nasal applicator.
- 2. Wash the applicator and dust cover under warm tap water. Allow to dry at room temperature, then place the applicator and dust cover back on the bottle.
- 3. If the nasal applicator becomes blocked, it can be removed as above and left to soak in warm water. Rinse with cold tap water, dry, and refit. **Do not try to unblock the nasal applicator by inserting a pin or other sharp object.**

#### **STORING YOUR NASAL SPRAY**

- \* Keep your FLONASE Nasal Spray out of the reach of children.
- Avoid spraying in eyes.
- ♦ Store between 4° and 30°C (39° and 86°F).
- Do not use your FLONASE Nasal Spray after the date shown as "EXP" on the label or box.

REMEMBER: This medicine has been prescribed for you by your doctor. DO NOT give this medicine to anyone else.

### FURTHER INFORMATION

This leaflet does not contain the complete information about your medicine. *If you have any questions, or are not sure about something, then you should ask your doctor or pharmacist.* 

You may want to read this leaflet again. Please DO NOT THROW IT AWAY until you have finished your medicine.



GlaxoSmithKline Research Triangle Park, NC 27709

©2003, GlaxoSmithKline. All rights reserved.

July 2003

RL-2019